Skip to content Skip to footer
Subscribe Now
Exclusive Interview_Dr. Mónica Domínguez_2025
EXCLUSIVE

Exclusive: Dr. Mónica Domínguez from Smile Train in a Stimulating Conversation with PharmaShots on Why a Healthy Mouth is a Happy Mind

Shots:  Smile Train is a proud partner of the FDI World Dental Federation's annual World Oral Health Day Campaign, which is focusing this year on the theme "A Happy Mouth is a Happy Mind" to promote the importance of oral health and mental health  Through this campaign, Smile Train's goal is to educate the world…
March 20, 2025

Read more

Thoughtspot_Saurabh_Chaubey
THOUGHTSPOT

Role of Digital Twin Technology in Healthcare

Shots:  Developments in healthcare technologies are setting new standards at present and encouraging exploration into emerging technologies to advance care and enhance the lives of patients globally  Digital Twins are virtual replicas of objects, individuals, or systems spanning their life cycles  The article introduces the role of digital twins in the healthcare system, the advantages,…
March 19, 2025

Read more

Viewpoints_Uwe Gudat
VIEWPOINTS

Biocon Biologics at AAO 2024: Uwe Gudat in an Invigorating Discussion with PharmaShots

Shots: At the American Academy of Ophthalmology (AAO 2024), Biocon Biologics announced promising results from the extension study of its proposed biosimilar to aflibercept, MYL-1701P The study demonstrated comparable safety, efficacy, and immunogenicity between patients continuing MYL-1701P and those who switched from aflibercept to MYL-1701P Biocon Biologics' Chief Medical Officer, Uwe Gudat, discusses the groundbreaking…
March 17, 2025

Read more

Spotlight Interview_T.J.Sharpe
EVENTS

Reuters Pharma USA 2025: Pre Conference Talks featuring T.J. Sharpe

With breakthrough discoveries addressing patients' unmet needs, caregivers, decision-makers, and advocacy groups have made great strides towards bringing patient experience to the mainstream.  Today's guest is TJ Sharpe, a Patient Insights Expert and Stage-IV Melanoma survivor. In his topic "Complicating is easy, Simplifying is Difficult, the personalized patient experience", T.J. will shed light on patient…
March 13, 2025

Read more

Exclusive_Kenneth-Sake_2025
EXCLUSIVE

Exclusive: Kenneth Sake from Blueprint Medicines in an Enlightening Conversation with PharmaShots

Highlights:  Systemic mastocytosis (SM) is a rare disease caused by the abnormal accumulation of mast cells – a key part of the body’s immune system People with SM face potentially debilitating symptoms, such as skin lesions, diarrhoea, bone pain, fatigue and anaphylaxis, which can present challenges across various aspects of patients’ lives For more than…
March 12, 2025

Read more

Viewpoints_Caterina Brindicci
VIEWPOINTS

Enhancing Autoimmune Care: Caterina Brindicci from AstraZeneca in a Riveting Conversation with PharmaShots

Shots:   SLE-related diseases like CLE and IIM are characterized by strong type I interferon involvement. The proven efficacy of Saphnelo (anifrolumab) in SLE lays the foundation for its potential use in CLE and IIM  Recently, AstraZeneca initiated two new P-III trials, LAVENDER and JASMINE, to evaluate Saphnelo in cutaneous lupus erythematosus and idiopathic inflammatory myopathies …
March 3, 2025

Read more

Viewpoints_Mina Makar
VIEWPOINTS

A Retrospective Analysis on Cardiac Amyloidosis: Mina Makar from AstraZeneca in an Illuminating Conversation with PharmaShots

Shots:  A UK observational study spanning 17 years shows a 2.9-fold increase in Cardiac Amyloidosis diagnoses, highlighting significant progress in awareness among healthcare professionals and advancements in diagnostic tools  The study underscores the importance of improving the identification and treatment of Cardiac Amyloidosis, particularly in cases with overlapping conditions such as heart failure  Mina Makar,…
February 24, 2025

Read more

Viewpoints_Stephanie Fradette
VIEWPOINTS

Biogen at WMS 2024: Stephanie Fradette from Biogen in an Illuminating Dialogue Exchange with PharmaShots

Shots:  Biogen recently shared findings from the P-II/III DEVOTE study, which investigated the safety and efficacy of a higher dose regimen of Spinraza for the treatment of spinal muscular atrophy (SMA)  Stephanie Fradette, Head of Neuromuscular Development Unit at Biogen, joins PharmaShots for a stimulating conversation on Biogen's groundbreaking presentation at World Muscle Society 2024. …
February 19, 2025

Read more

Viewpoints_Mina Makar
VIEWPOINTS

Curbing Misfolded TTR with RNA Therapy: Mina Makar from AstraZeneca in a Stimulating Conversation with PharmaShots

Shots:  Misfolded TTR can lead to chronic conditions like ATTRv-PN or ATTR-CM. AstraZeneca’s Wainua (eplontersen) is a once-a-month RNA-targeted medication that suppresses TTR production  Mina Makar SVP and Commerical Lead of the Global Cardiovascular, Renal, and Metabolism (CVRM), Biopharmaceuticals Business Unit at AstraZeneca, sheds light on eplontersen and its ongoing P-III clinical trial on ATTR-CM …
February 17, 2025

Read more

Load more